

REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)

RECEIVED
 JAN 02 2001
 File Information Unit

In re Application of <i>Bendig</i>	
Application Number <i>08/186269</i>	Filed <i>11/21/98</i>
Group Art Unit	Examiner

Paper No. *#19*

Assistant Commissioner for Patents
 Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE)

- ___ (A) referred to in United States Patent Number *5840299*, column _____,
- ___ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. _____, filed _____, on page _____ of paper number _____,
- ___ (C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. _____, filed _____, or
- ___ (D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

Nancy Perry

 Signature
Nancy Perry

 Typed or printed name

1/2/01

 Date

FOR PTO USE ONLY
Approved by: <i>[Signature]</i>
File Information Unit
Unit: _____



US005840299A

United States Patent [19]

Bendig et al.

[11] **Patent Number:** 5,840,299[45] **Date of Patent:** Nov. 24, 1998[54] **HUMANIZED ANTIBODIES AGAINST
LEUKOCYTE ADHESION MOLECULE
VLA-4**[75] Inventors: **Mary M. Bendig**, London; **Olivier J. Léger**, Hertfordshire; **José Saldanha**, Enfield Middlesex; **S. Tarran Jones**, Radlett, all of United Kingdom; **Ted A. Yednock**, Fairfax, Calif.[73] Assignee: **Athena Neurosciences, Inc.**, South San Francisco, Calif.

[21] Appl. No.: 561,521

[22] Filed: Nov. 21, 1995

Related U.S. Application Data

[63] Continuation-in-part of Ser. No. 186,269, which is a continuation-in-part of PCT/US95/01219 Jan. 25, 1995, abandoned.

[51] Int. Cl.⁶ **A61K 39/395**; C07K 16/28; C12P 21/08; C12N 15/13[52] U.S. Cl. **424/133.1**; 424/130.1; 424/141.1; 424/143.1; 424/144.1; 424/153.1; 424/154.1; 424/173.1; 435/7.1; 435/7.2; 435/7.21; 435/7.24; 435/69.6; 435/172.3; 435/251.3; 435/320.1; 530/387.3; 530/388.73; 530/388.75; 530/388.22; 536/23.53

[58] Field of Search 424/130.1, 133.1, 424/141.1, 143.1, 144.1, 153.1, 154.1, 173.1; 435/69.6, 172.3, 252.3, 320.1, 7.1, 7.2, 7.21, 7.24; 536/23.4, 23.5, 23.53; 530/387.1, 387.3, 388.2, 388.22, 388.7, 388.73, 388.75

[56] **References Cited****U.S. PATENT DOCUMENTS**5,260,210 11/1993 Rubin et al. 435/240.23
5,530,101 6/1996 Queen et al. 530/387.3**FOREIGN PATENT DOCUMENTS**239400 9/1987 European Pat. Off. C12N 15/00
330506 8/1989 European Pat. Off. C07K 15/06
XWO 90/07861 7/1990 WIPO C12P 21/00
XWO 91/03252 3/1991 WIPO A61K 37/10
91/05038 4/1991 WIPO C12N 5/06
XWO 93/15764 8/1993 WIPO A61K 39/395**OTHER PUBLICATIONS**X Lisak et al. J. Neurol. Sciences 62: 281-293 (1983).
X Teitelbaum et al. PNAS 89: 137-141 (1992).
X Weiner et al. Science 259: 1321-1324 (1993).
X Racke et al. J. Neuroimmunol. 46: 175-184 (1993).
X Karussis et al. PNAS 90: 6400-6404 (1993).X Cannella et al. Ann Neurol. 37: 424-435 (1995).
X Washington et al. Ann Neurol 35: 89-97 (1994).
X Dore-Duffy et al. in Frontiers in Cerebral Vascular Biology: Transport and its Regulation (eds) Dreues and Betz Plenum Press Ny 1993 pp. 243-248.
X Monshizadegan et al., "VLA-4-dependent adhesion activities of U937 cells and guinea pig bronchoalveolar lavage leukocytes", 1993. *Agents Actions* 39, pp. C177-C179.
X Kettleborough et al., "Humanization of a mouse monoclonal antibody by CDR-grafting the importance of framework residues on loop conformation", 1991. *Protein Engineering*, vol. 4, No. 7, pp. 773-783.
Yednock et al. "Prevention of experimental autoimmune encephalomyelitis by antibodies against $\alpha 4 \beta 1$ integrin", 1991. *Letters to Nature*, vol. 356, pp. 63-66.
W. J. Harris and S. Emery. "Therapeutic antibodies—the coming of age", 1993. *Tibtech*, vol. 11, pp. 42-45.
S. C. Emery and J. R. Adair. "Humanised monoclonal antibodies for therapeutic applications", 1994. *Exp. Opin. Invest. Drugs*, vol. 3, pp. 241-251.
S. M. Edgington. "How Sweet It Is: Selectin-Mediating Drugs", 1992. *Bio/Technology*, vol. 10, pp. 383-389.
Elices et al., "VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA-4 at a Site Distinct from the VLA-4/Fibronectin Binding Site", 1990. *Cell*, vol. 60, pp. 577-584.
Dijkstra et al., "Multiple sclerosis: some possible therapeutic opportunities", 1993. *Tips Reviews*, vol. 14, pp. 124-129.
A. Mountain and J.R. Adair. "Engineering Antibodies for Therapy", 1992. *Biotech Genetic Engineering Reviews*, vol. 10, pp. 10-13.
P.A. Ward and M.S. Mulligan. "Blocking of adhesion molecules in vivo as anti-inflammatory therapy", 1994. *Therapeutic Immunol*, vol. 10, pp. 165-171.
L. K. Jolliffe. "Humanized Antibodies: Enhancing Therapeutic Utility Through Antibody Engineering", 1993. *Intern Rev Immunol*, vol. 10, pp. 241-250.
X Albelda Faseb J. 8: 504-512 (1994).
X Kahan Curr Opin Immunology 4: 553-560 (1992).
X Natanson et al. Ann Intern Med. 120: 771-783 (1994).
X Dalakas Ann. Neurol. 37(51): 52-513 (1995).
X Paul (ed) Fundamental Immunology Raven Press NY 1993 p. 242 only.**Primary Examiner**—Lila Feisee**Assistant Examiner**—Phillip Gambel**Attorney, Agent, or Firm**—Townsend & Townsend & Crew LLP

[57]

ABSTRACT

The invention provides humanized immunoglobulins that specifically bind to the VLA-4 ligand, and methods of treatment using the same. The methods are particularly useful for treatment of multiple sclerosis.

29 Claims, 16 Drawing Sheets